The U.S. Food and Drug Administration held a public hearing on Friday as the agency continues its work to regulate CBD following the legalization of hemp in the 2018 Farm Bill in December. Although the legislation removed hemp and derivatives containing less than 0.3 percent THC, the 2018 Farm Bill also granted the FDA the authority to regulate cannabis compounds including CBD. The agency then announced that CBD could not be used as a dietary supplement or ingredient in foods until regulations have been drafted. Friday’s hearing was the first opportunity for members of the public to provide input to the agency on the subject.
In a Federal Register notice requesting comments from the public at the hearing, the FDA noted that more research is needed on CBD.
“Questions remain regarding the safety considerations raised by the widespread use of these products,” the notice reads. “These questions could impact the approaches we consider taking in regulating the development and marketing of products.”
Potential Risks of CBD
The FDA has approved one prescription CBD medication, Epidiolex, for the treatment of severe epilepsy. In clinical trials for the drug, high doses of CBD were generally well tolerated by patients but some did